The US prevalence of idiopathic intracranial hypertension increased significantly between 2015 and 2022. Black and Hispanic women experienced the greatest increases, new research revealed.
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.
Novo Nordisk s blockbuster
diabetes drug Ozempic and weight-loss therapy Wegovy are being
studied to see whether they can improve health in other ways. Both treatments contain the active.
New data suggests that semaglutide may also cut the risk of stroke or heart attack, and may delay the progression of kidney disease in diabetes patients.